Amit Kumar Acquires 5,000 Shares of Anixa Biosciences Inc (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 5,000 shares of the stock in a transaction dated Friday, July 11th. The shares were purchased at an average cost of $3.15 per share, for a total transaction of $15,750.00. Following the completion of the acquisition, the chief executive officer directly owned 574,925 shares in the company, valued at approximately $1,811,013.75. This trade represents a 0.88% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Wednesday, June 4th, Amit Kumar acquired 10,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $2.85 per share, with a total value of $28,500.00.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock traded down $0.01 during trading on Thursday, reaching $3.35. 129,544 shares of the stock traded hands, compared to its average volume of 105,547. The company has a market capitalization of $107.90 million, a price-to-earnings ratio of -8.82 and a beta of 0.39. The business has a fifty day simple moving average of $3.04 and a two-hundred day simple moving average of $2.87. Anixa Biosciences Inc has a 52-week low of $2.07 and a 52-week high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, research analysts predict that Anixa Biosciences Inc will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ANIX. Maxim Group began coverage on Anixa Biosciences in a research note on Friday, March 21st. They issued a "buy" rating and a $10.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, March 25th. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 10th. Finally, Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $9.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Advisor Group LLC purchased a new position in shares of Anixa Biosciences during the first quarter valued at approximately $35,000. Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $26,000. Focus Partners Wealth purchased a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $162,000. Jane Street Group LLC bought a new stake in shares of Anixa Biosciences during the fourth quarter valued at approximately $67,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Hedge funds and other institutional investors own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.